Could cause temporary or reversible harm; serious harm is unlikely.
Lack of Assurance of Sterility: Nephron Pharmaceuticals Corporation conducted a routine periodic aseptic process simulation and discovered bacterial growth in a number of media fill vials, exceeding the allowable limit.
| Brand name | ALBUTEROL SULFATE |
| Generic name | ALBUTEROL SULFATE |
| Active ingredient(s) | ALBUTEROL SULFATE |
| Distributed by / for | Nephron Pharmaceuticals Corp. |
| NDC | 0487-9501-25 |
| Full product label | Albuterol Sulfate Inhalation Solution, 0.083% 2.5 mg/3 mL for Oral Inhalation Only, Rx Only, 25 x 3 mL Sterile Unit-Dose Vials per carton, Manufactured By: Nephron Pharmaceuticals Corporation, Orlando, FL 32811, NDC 0487-9501-25 |
| Recalling firm | Nephron Pharmaceuticals Corp. |
| Distribution | Nationwide and Puerto Rico |
| Quantity | 689,568 cartons |
| Recall initiated | 2013-10-02 |
| Report date | 2013-10-30 |
| Recall completed | 2015-08-21 |
| Recall number | D-66462-001 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Orlando FL United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗